The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia. UCB7665, Rozanolixizumab, works by binding with high-affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling.

Australia, Belgium, Bulgaria, Czechia, Georgia, Germany, Italy, Lithuania, Republic of Moldova, Poland, Romania, Spain, United Kingdom

https://clinicaltrials.gov/ct2/show/NCT02718716?recrs=a&cond=ITP&draw=1&rank=33

Recruiting